Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,201–3,300 of 15,747
Ge, N., Sun, J., Liu, Z., Shu, J., Yan, H., Kou, Z., Yu, W., & Jin, X. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.01.032 · Cited by 34
Role of circular RNAs in cancer therapy resistance
Liu, W., Niu, J., Huo, Y., Zhang, L., Han, L., Zhang, N., & Yang, M. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02254-5 · Cited by 45
“The remarkable success of RNA vaccines in fighting the COVID-19 pandemic has paved the way for circRNA vaccine research [274].”
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Liu, H.-L., Wei, P., Zhang, Q.-Q., et al. (2021) · bioRxiv · doi:10.1101/2021.02.16.431305 · Cited by 80
Vitiligo in a COVID‐19‐vaccinated patient with ulcerative colitis: coincidence?
Aktaş, H., & Ertuğrul, G. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14842 · Cited by 33
Thakur, K. T., Tamborska, A., Wood, G. K., McNeill, E. N., Roh, D. J., Akpan, I. J., Miller, E. C., Bautista, A. E., Claassen, J., Kim, C. Y., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117532 · Cited by 40
“Importantly, new onset headache, one of the non-specific but cardinal features of CVT, is seen in up to 67% of individuals during the initial few days after any COVID-19 vaccination (6, 7).”
BackgroundCutaneous and Allergic reactions due to COVID‐19 vaccinations: A review
Temiz, S. A., Abdelmaksoud, A., Wollina, U., Kutlu, Ö., Dursun, R., Patil, A. D., Lotti, T., Goldust, M., & Vestita, M. G. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14613 · Cited by 34
Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers
Ferris, M., Ferris, R., Workman, C., O'Connor, E., Enoch, D., Goldesgeyme, E., Quinnell, N., Patel, P., Wright, J., Martell, G., et al. (2021) · eLife · doi:10.7554/elife.71131 · Cited by 38
“To avoid the potential for confounding, the final week of the study period commenced on 11/01/21, since minimal effect is expected in the first seven days after the first dose of vaccine [16].”
BackgroundSubacute cutaneous lupus erythematosus flare triggered by COVID ‐19 vaccine
Joseph, A. K., & Chong, B. F. (2021) · Dermatologic Therapy · doi:10.1111/dth.15114 · Cited by 33
Campochiaro, C., Trignani, G., Tomelleri, A., Cascinu, S., & Dagna, L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219811 · Cited by 35
Opportunities and Challenges for mRNA Delivery Nanoplatforms
Zhang, Y., Hu, Y., Tian, H., & Chen, X. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c03898 · Cited by 35
Wang, J., Zhang, Q., Ai, J., Liu, D., Liu, C., Xiang, H., Gu, Y., Guo, Y., Lv, J., Huang, Y., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10332-9 · Cited by 33
“6% (196) of 30,351 participants in the mRNA-1273 vaccine trial [4, 6].”
BackgroundKartnig, F., Mrak, D., Simader, E., Tobudic, S., Radner, H., Mandl, P., Göschl, L., Hommer, N., Mayer, M., Hofer, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222682 · Cited by 31
Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine
Hines, A., Shen, J. G., Olazagasti, C., et al. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242678 · Cited by 33
Adults’ Acceptance of COVID-19 Vaccine for Children in Selected Lower- and Middle-Income Countries
Bono, S. A., Siau, C. S., Chen, W. S., Low, W. Y., Villela, E. F. D. M., Pengpid, S., Hasan, M. T., Sessou, P., Ditekemena, J., Amodan, B. O., et al. (2021) · Vaccines · doi:10.3390/vaccines10010011 · Cited by 37
“The 95% level was chosen based on the initial results of the COVID-19 messenger RNA (mRNA) vaccines showing an effectiveness of 95% [22], the 50% level is the minimum level for a vaccine to be approved [23], and the 75% level is an intermediate level where vaccination could be considered depending on severity of the d…”
MethodCurrent state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 39
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 34
Cassaniti, I., Bergami, F., Percivalle, E., Gabanti, E., Sammartino, J. C., Ferrari, A., Adzasehoun, K. M. G., Zavaglio, F., Zelini, P., Comolli, G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.016 · Cited by 38
“The mRNA BNT162b2 vaccine [1], the first authorized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, showed 95% protection against SARS-CoV-2 infection in a phase II/III trial [2].”
A new dawn for monoclonal antibodies against antimicrobial resistant bacteria
Troisi, M., Marini, E., Abbiento, V., Stazzoni, S., Andreano, E., & Rappuoli, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1080059 · Cited by 41
“, 2005, 2011), led to a breakthrough in 2020, when two mRNA-based vaccines against SARS-CoV-2 were the first-in-class approved products available worldwide to fight the ongoing COVID-19 pandemic (Polack et al., 2020; Baden et al., 2021).”
BackgroundEvolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
Antunes, R. D. S., Fajardo-Rosas, V., Yu, E. D., Gálvez, R. I., Abawi, A., Escarrega, E. A., Martínez-Pérez, A., Johansson, E., Goodwin, B., Frazier, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115907 · Cited by 41
Pityriasis rosea after mRNA COVID‐19 vaccination
Abdullah, L., Hasbani, D. J., Kurban, M., & Abbas, O. M. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15700 · Cited by 34
Nassir, C. M. N. C. M., Hashim, S., Wong, K. K., Halim, S. A., Idris, N. S., Jayabalan, N., Guo, D., & Mustapha, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02457-z · Cited by 37
“1% efficacy [31] and BNT162b2 (Pfizer/BioNTech) with 95% efficacy [32] with emergence use approvals by regulatory bodies in over 70 countries worldwide to date and counting.”
BackgroundThe impact of COVID ‐19 vaccine on sperm quality
Barda, S., Laskov, I., Grisaru, D., Lehavi, O., Kleiman, S. E., Wenkert, A., Azem, F., Hauser, R., & Michaan, N. (2022) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14135 · Cited by 35
Gilham, D., Smith, A. L., Fu, L., Moore, D. Y., Muralidharan, A., Reid, S. P., Stotz, S. C., Johansson, J. O., Sweeney, M., Wong, N. C. W., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040437 · Cited by 32
Beigi, A., Yousefpour, A., Yasami, A., Gómez-Aguilar, J. F., Bekiros, S. D., & Jahanshahi, H. (2021) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-021-01620-8 · Cited by 32
“According to the research in [62], we assume vaccine efficacy ev 0.”
BackgroundWagner, A. L., Gorin, S. S., Boulton, M. L., Glover, B. A., & Morenoff, J. D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917233 · Cited by 34
Jiang, W., Shi, L., Cai, L., Wang, X., Li, J., Li, H., Liang, J., Gu, Q., Ji, G., Li, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110112 · Cited by 33
“Numerous vaccines are being developed to control this disease, with development at different stages ranging from preclinical studies and phase I–III trials to launch in the marketplace for emergency use (Krammer, 2020; Polack et al., 2020; Ramasamy et al., 2021).”
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 39
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 36
“Pfizer/BioNTech mRNA Vaccine The BNT162b2 that belongs to the mRNA vaccine can transcribe and translate the full-length S protein, reaching 95% efficacy against COVID-19 (156).”
BackgroundBlain, H., Tuaillon, É., Gamon, L., Pisoni, A., Miot, S., Rolland, Y., Picot, M., & Bousquet, J. J. (2021) · Allergy · doi:10.1111/all.15007 · Cited by 36
Francica, J. R., Flynn, B. J., Foulds, K. E., Noe, A. T., Werner, A. P., Moore, I. N., Gagne, M., Johnston, T. S., Tucker, C., Davis, R. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.02.433390 · Cited by 33
mRNA vaccines induce rapid antibody responses in mice
Gebre, M. S., Rauch, S., Roth, N., Gergen, J., Yu, J., Liu, X., Cole, A. C., Mueller, S. O., Petsch, B., & Barouch, D. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00511-y · Cited by 34
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment
Lang, X., Wang, X., Han, M., & Guo, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455213 · Cited by 38
Moghadas, S. M., Fitzpatrick, M. C., Shoukat, A., Zhang, K., & Galvani, A. P. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.7097 · Cited by 35
Halfmann, P., Loeffler, K., Duffy, A., Kuroda, M., Yang, J. E., Wright, E., Kawaoka, Y., & Kane, R. S. (2024) · Nature Communications · doi:10.1038/s41467-024-45495-6 · Cited by 33
Vaccine Effectiveness of Two and Three Doses of BNT162b2 and Coronavac Against COVID-19 in Hong KongPreprint
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4064649 · Cited by 32
Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants
Fleming-Dutra, K. E., Zauche, L. H., Roper, L. E., Ellington, S., Olson, C. K., Sharma, A. J., Woodworth, K. R., Tepper, N. K., Havers, F. P., Oliver, S. E., et al. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2023.02.003 · Cited by 36
Olfactory immune response to SARS-CoV-2
Wellford, S. A., & Moseman, E. A. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01119-5 · Cited by 37
Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity
Dvorscek, A. R., McKenzie, C. I., Stäheli, V. C., Ding, Z., White, J., Fabb, S. A., Lim, L., O’Donnell, K., Pitt, C., Christ, D., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.017 · Cited by 33
Klimek, L., Bergmann, K., Brehler, R., Pfützner, W., Zuberbier, T., Hartmann, K., Jakob, T., Novak, N., Ring, J., Merk, H. F., et al. (2021) · Allergo Journal International · doi:10.1007/s40629-021-00165-7 · Cited by 35
Shimizu, K., Iyoda, T., Sanpei, A., Nakazato, H., Okada, M., Ueda, S., Kato-Murayama, M., Murayama, K., Shirouzu, M., Harada, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02885-6 · Cited by 36
Lian, Z., Zheng, L., Liu, S., Zhang, J., Zhou, J. J., Wu, J., Ouyang, S., Li, J., & Yang, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05367 · Cited by 37
Miliotou, Α. N., Pappas, I. S., Spyroulias, G. A., Vlachaki, E., Tsiftsoglou, A. S., Vizirianakis, I. S., & Papadopoulou, L. C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.09.008 · Cited by 34
Martin, W. R., & Cheng, F. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1894986 · Cited by 36
Perrier, Q., Lupo, J., Gerster, T., Augier, C., Falque, L., Rostaing, L. P. E., Pelletier, L., Bedouch, P., Blanc, M., Saint‐Raymond, C., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.065 · Cited by 36
Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo
Wu, S., Su, K., Yan, X., Shi, L., Lin, L., Ren, E., Zhou, J., Zhang, C., Song, Y., & Liu, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.028 · Cited by 35
Focusing COVID-19 vaccinations on elderly and high-risk people
Brenner, H. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100044 · Cited by 33
A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects
Lentzen, M.-P., Huebenthal, V., Kaiser, R., Kreppel, M., Zöeller, J. E., & Zirk, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.052 · Cited by 39
“These mild effects occur by about 70% after the first injection and about 65% after the second dose [33].”
BackgroundWhat We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Yoo, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e54 · Cited by 40
Darney, B. G., Boniface, E. R., van Lamsweerde, A., Han, L. L., Matteson, K. A., Cameron, S. T., Male, V. H., Acuna, J. M., Benhar, E., Pearson, J. T., et al. (2023) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17471 · Cited by 35
Sohi, A. N., Kiani, J., Arefian, E., Khosrojerdi, A., Fekrirad, Z., Ghaemi, S., Zim, M. K., Jalili, A., Bostanshirin, N., & Soleimani, M. (2021) · Vaccines · doi:10.3390/vaccines9091007 · Cited by 32
Canetti, M., Barda, N., Gilboa, M., Indenbaum, V., Mandelboim, M., Gonen, T., Asraf, K., Weiss-Ottolenghi, Y., Amit, S., Doolman, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35480-2 · Cited by 37
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
Sadeghalvad, M., Mansourabadi, A. H., Noori, M., Nejadghaderi, S. A., Masoomikarimi, M., Alimohammadi, M., & Rezaei, N. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2359 · Cited by 42
“After selection of BNT162b2 for further advancement to safety and efficacy evaluation, a phase II/III trial was conducted in a multicenter setting for participants aged 16 or older.(41) The overall efficacy was estimated to be 95%.”
MethodSingle-Molecule FRET Imaging of Virus Spike–Host Interactions
Lu, M. (2021) · Viruses · doi:10.3390/v13020332 · Cited by 40
Ruhe, J., Schnetzke, U., Kentouche, K., Prims, F., Baier, M., Herfurth, K., Schlosser, M., Busch, M., Hochhaus, A., & Wolf, G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04584-y · Cited by 32
“Furthermore, Sissa et al. reported about a relapse of TTP 6 days after the second dose administration of BNT162b2 [8].”
BackgroundInfluentialImmunogenicity and safety of coadministration of COVID-19 and influenza vaccination
Wagenhäuser, I., Reusch, J., Gabel, A., Höhn, A., Lâm, T., Almanzar, G., Prelog, M., Krone, L. B., Frey, A., Schubert‐Unkmeir, A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01390-2022 · Cited by 32
Khairullin, B. M., Zakarya, K. D., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M. M., Sarsenbayeva, G., Sultankulova, K. T., Chervyakova, O. V., Myrzakhmetova, B. S., Куралбаевич, Н. А., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101526 · Cited by 39
Pušnik, J., Zorn, J., Monzon‐Posadas, W. O., Peters, K., Osypchuk, E., Blaschke, S., & Streeck, H. (2024) · Nature Communications · doi:10.1038/s41467-024-47451-w · Cited by 43
Brdovčak, M. C., Materljan, J., Šustić, M., Ravlić, S., Ružić, T., Lisnić, B., Miklić, K., Brizić, I., Matešić, M. P., Lisnić, V. J., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202249823 · Cited by 35
COVID-19 vaccine mandate for healthcare workers in the United States: a social justice policy
Hagan, K., Forman, R., Mossialos, E. A., Ndebele, P., Hyder, A. A., & Nasir, K. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.1999811 · Cited by 36
Izumo, T., Kuse, N., Awano, N., Tone, M., Sakamoto, K., Takada, K., Muto, Y., Fujimoto, K., Saiki, A., Ito, Y., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.06.003 · Cited by 31
“Compared with the side effects reported in previous overseas studies about the BNT162b2 mRNA COVID-19 vaccine [4], similar side effects were observed for the Japanese participants in this study.”
InfluentialPityriasis rosea‐like eruption after Pfizer–BioNTech COVID‐19 vaccination
Vázquez, A. M. C., & Morgado, B. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20143 · Cited by 32
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
Rammensee, H., Gouttefangeas, C., Heidu, S., Klein, R., Preuß, B. E., Walz, J. S., Nelde, A., Haen, S. P., Reth, M. G., Yang, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050428 · Cited by 29
“For example, hitherto unapproved approaches and vaccine platforms initially intended for immune oncology applications and other diseases were swiftly repurposed, which enabled the development of COVID-19 vaccines at an unprecedented pace [3,4].”
BackgroundmRNA-based vaccine technology for HIV
Albert-Ludwigs-Universität Freiburg, G., Fortner, A., & Bucur, O. (2022) · Discoveries · doi:10.15190/d.2022.9 · Cited by 41
Lee, K. Y., Dabak, S. V., Kong, V. H., Park, M., Kwok, S. L. L., Silzle, M., Rachatan, C., Cook, A. R., Passanante, A., Pertwee, E., et al. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00843-6 · Cited by 42
“The COVID-19 vaccine chatbot content covered seven major categories of commonly asked questions: (1) Importance/Necessity, (2) Safety, (3) Effectiveness, (4) How to get vaccinated, (5) Tips before vaccination, (6) Tips after vaccination, and (7) Debunking COVID-19 vaccine-related misinformation.”
BackgroundB- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents
Torres, I., Albert, E., Giménez, E., Alcaráz, M. J., Botija, P., Amat, P., Remigia, M. J., Beltrán, M. J., Rodado, C., Huntley, D., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.013 · Cited by 39
“The efficacy of the vaccine has been shown to approach 95% inpreventing COVID-19 across a wide range of age groups [5].”
Mitsunaga, T., Ohtaki, Y., Seki, Y., Yoshioka, M., Mori, H., Suzuka, M., Mashiko, S., Takeda, S., & Mashiko, K. (2021) · PeerJ · doi:10.7717/peerj.12316 · Cited by 35
“BNT162b2 is a new generation vaccine with nucleoside-modified RNA molecules encoding the full-length SARS-CoV-2 spike glycoprotein (Polack et al., 2020).”
BackgroundMENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
Yamout, B., Zakaria, M. F., Inshasi, J. S. S., Al-Jumah, M., Zeineddine, M. M., Dahdaleh, M., Bohlega, S., Gouider, R., & Alroughani, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103225 · Cited by 34
Mucosal vaccine development for respiratory viral infections
Lin, Y., Hu, Z., Fu, Y., & Peng, H. (2023) · hLife · doi:10.1016/j.hlife.2023.12.005 · Cited by 35
Pan, X., Shi, J. R., Hu, X., Wu, Y. L., Zeng, L., Yao, Y., Shang, W., Liu, K., Gao, G., Guo, W., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00320-y · Cited by 30
Hall, V. G., Solera, J. T., Al-Alahmadi, G., Marinelli, T. M., Cardinal, H., Poirier, C. D., Huard, G., Prasad, G. V. R., Serres, S. A. D., Isaac, D., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.220620 · Cited by 32
Gu, W., An, J., Li, Y., Yang, Y., Wang, S., Shan, H., Li, S., Li, H., Liu, G., Li, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202301686 · Cited by 41
Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments
Garaizar, A., Díaz‐Oviedo, C. D., Zablowsky, N., Rissanen, S., Köbberling, J., Sun, J., Steiger, C., Steigemann, P., Mann, F. A., & Meier, K. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404555121 · Cited by 40
Bradley, T., Grundberg, E., CODIEFY study team, & Selvarangan, R. (2021) · medRxiv · doi:10.1101/2021.02.03.21251078 · Cited by 32
Bianchi, F. P., Tafuri, S., Migliore, G., Vimercati, L., Martinelli, A., Lobifaro, A., Diella, G., Control Room Working Group, & Stefanizzi, P. (2021) · Vaccines · doi:10.3390/vaccines9101143 · Cited by 32
“Aside from transient local and systemic reactions, no safety issues were identified [8]; however, no information was released on the vaccine’s efficacy against documented Sars-CoV-2 infection.”
Background(2021) · doi:10.1101/2021.03.30.21254655 · Cited by 49
SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision
Wang, E. W., Parchem, J. G., Atmar, R. L., & Clark, E. H. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab180 · Cited by 33
Jacob-Dolan, C., Feldman, J. E., McMahan, K., Yu, J., Zahn, R. C., Wegmann, F., Schuitemaker, H., Schmidt, A. G., & Barouch, D. H. (2021) · Journal of Virology · doi:10.1128/jvi.00117-21 · Cited by 34
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
“In contrast, RNA-based vaccines do not interfere with the genome, but are less stable and may require additional support for optimal function, such as cold-chain storage and booster shots (2, 13, 14).”
BackgroundInfluentialPassing the Test: A Model-Based Analysis of Safe School-Reopening Strategies
Bilinski, A., Salomon, J. A., Giardina, J., Ciaranello, A. L., & Fitzpatrick, M. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0600 · Cited by 38
“In addition to classroom quarantine, teacher susceptibility was reduced to 33% of baseline, roughly assuming that 75% of teachers receive an infection-blocking vaccine with 90% effectiveness (48, 49, 57).”
BackgroundMelo, P., Barbosa, J. M., Jardim, L., Carrilho, E., & Portugal, J. (2021) · International Dental Journal · doi:10.1016/j.identj.2021.01.015 · Cited by 44
Bioinspired Spatiotemporal Management toward RNA Therapies
Ma, Y., Li, S., Lin, X., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c08219 · Cited by 33
Butt, A. A., Peng, Y., Shaikh, O. S., & Mayr, F. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101117 · Cited by 36
“Clinical trials for vaccine efficacy have shown the vaccines to be highly protective against severe disease and death, with efficacy approaching 100% for these outcomes [1,2].”
Efficient delivery of VEGFA mRNA for promoting wound healing via ionizable lipid nanoparticles
Dong, S., Wang, J., Guo, Z., Zhang, Y., Zha, W., Wang, Y., Liu, C., Xing, H., & Li, X. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117135 · Cited by 35
Impact of COVID-19 on Dental Care during a National Lockdown: A Retrospective Observational Study
Walter, E., von Bronk, L., Hickel, R., & Huth, K. C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157963 · Cited by 33
“Even though vaccines became available in January 2021, the population remains in a state of uncertainty because of several new COVID-19 variants [9,10].”
BackgroundPotential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 39
“3 mL) [109,159,169] Dosing Schedule Day 1, Day 29 Day 1, Day 21”
BackgroundFeatures of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level
Chouchana, L., Blet, A., Al-Khalaf, M. H., Kafil, T. S., Nair, G. M., Robblee, J. A., Drici, M., Valnet‐Rabier, M., Micallef, J., Salvo, F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2499 · Cited by 36
Malden, D. E., Liu, I. A., Qian, L., Sy, L. S., Lewin, B. J., Asamura, D. T., Ryan, D. S., Bezi, C., Williams, J. T. B., Kaiser, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48022-9 · Cited by 35
Cabreira, V., Abreu, P., Soares-dos-Reis, R., Guimarães, J., & Sá, M. J. (2021) · Vaccines · doi:10.3390/vaccines9070773 · Cited by 33
Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
Mahallawi, W. H., & Mumena, W. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.794642 · Cited by 31
Bonanni, P., Cantón, R., Gill, D., Halfon, P., Liebert, U. G., Crespo, K. A. N., Martín, J. J. P., & Trombetta, C. M. (2021) · COVID · doi:10.3390/covid1010004 · Cited by 38
Lanini, S., Capone, S., Antinori, A., Milleri, S., Nicastri, E., Camerini, R., Agrati, C., Castilletti, C., Mori, F., Sacchi, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1996 · Cited by 37
Bajwa, H. M., Novak, F., Nilsson, A. C., Nielsen, C., Holm, D. K., Østergaard, K., Witt, A. H., Byg, K., Johansen, I. S., Mittl, K., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103729 · Cited by 33
“All participants followed standard clinical practice by their treating neurologist and interval of time between second and third vaccination was not standardised (Baden et al., 2021; Polack et al., 2020).”
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Vorontsov, O. M., Zigron, R., Kleinstern, G., Wolf, D. G., & Porat, S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac135 · Cited by 35
Shen, L., Yang, J., Zuo, C., Xu, J., Ma, L., He, Q., Zhou, X., Ding, X., Wei, L., Jiang, S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.017 · Cited by 34
Gerotziafas, G., Catalano, M., Theodorou, Y., Dreden, P. V., Maréchal, V., Spyropoulos, A. C., Carter, C., Jabeen, N., Harenberg, J., Elalamy, I., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1535-8807 · Cited by 32
Panova, E. A., Kleymenov, D. A., Shcheblyakov, D. V., Bykonia, E. N., Mazunina, E. P., Dzharullaeva, A. S., Zolotar, A. N., Derkaev, A. A., Esmagambetov, I. B., Sorokin, I. I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1098302 · Cited by 40
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.